Abstract
1 The pharmacokinetics of diethylcarbamazine (DEC) were studied in twelve patients with chronic renal function impairment. 2 Selected pharmacokinetic parameters, plasma half-life (T1/2), area under the plasma concentration-time curve (AUC), elimination rate constant (Kel) and 24 h urinary excretion were regressed versus parameters indicative of renal function. 3 Significant negative correlations were observed between creatinine clearance and both plasma T1/2 and log10 T1/2. 4 Significant positive correlations were obtained between (a) creatinine clearance and elimination rate constant of DEC and (b) reciprocal serum creatinine and l/T1/2. Creatinine clearance was significantly and positively correlated with 24 h urinary excretion of DEC. 5 No significant correlations were observed between age, sex or weight and renal function but DEC excretion did appear to decrease with increasing urinary pH. 6 Plasma half-life, and area under the plasma concentration-time curve were increased and 24 h urinary excretion of DEC was significantly reduced in patients with chronic renal function impairment, compared with normal volunteer subjects receiving an identical dosage of DEC at acidic urinary pH.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Allen G. D., Goodchild T. M., Weatherley B. C. Determination of 1-diethylcarbamoyl-4-methylpiperazine (diethylcarbamazine) in human plasma and urine. J Chromatogr. 1979 Dec 1;164(4):521–526. doi: 10.1016/s0378-4347(00)81557-1. [DOI] [PubMed] [Google Scholar]
- BANGHAM D. R. Metabolism and excretion of 14C-labelled diethylcarbamazine. Br J Pharmacol Chemother. 1955 Dec;10(4):397–405. doi: 10.1111/j.1476-5381.1955.tb00093.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Beckett A. H., Rowland M. Urinary excretion kinetics of amphetamine in man. J Pharm Pharmacol. 1965 Oct;17(10):628–639. doi: 10.1111/j.2042-7158.1965.tb07575.x. [DOI] [PubMed] [Google Scholar]
- Edwards G., Awadzi K., Breckenridge A. M., Gilles H. M., Orme M. L., Ward S. A. Diethylcarbamazine disposition in patients with onchocerciasis. Clin Pharmacol Ther. 1981 Oct;30(4):551–557. doi: 10.1038/clpt.1981.202. [DOI] [PubMed] [Google Scholar]
- Edwards G., Breckenridge A. M., Adjepon-Yamoah K. K., Orme M. L., Ward S. A. The effect of variations in urinary pH on the pharmacokinetics of diethylcarbamazine. Br J Clin Pharmacol. 1981 Dec;12(6):807–812. doi: 10.1111/j.1365-2125.1981.tb01311.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Edwards G., Ward S. A., Breckenridge A. M., Orme M. L. Identification and quantification of diethylcarbamazine and diethylcarbamazine N-oxide in rat urine. Xenobiotica. 1981 Apr;11(4):281–284. doi: 10.3109/00498258109045303. [DOI] [PubMed] [Google Scholar]
- Fabre J., Balant L. Renal failure, drug pharmacokinetics and drug action. Clin Pharmacokinet. 1976;1(2):99–120. doi: 10.2165/00003088-197601020-00002. [DOI] [PubMed] [Google Scholar]
- Faulkner J. K., Smith K. J. Dealkylation and N-oxidation in the metabolism of i-diethylcarbamyl-4-methylpiperazine in the rat. Xenobiotica. 1972 Jan;2(1):59–68. doi: 10.3109/00498257209036234. [DOI] [PubMed] [Google Scholar]
- HAWKING F. Some recent work on filariasis. Trans R Soc Trop Med Hyg. 1950 Sep;44(2):153–192. doi: 10.1016/0035-9203(50)90044-7. [DOI] [PubMed] [Google Scholar]
- Reidenberg M. M. The binding of drugs to plasma proteins from patients with poor renal function. Clin Pharmacokinet. 1976;1(2):121–125. doi: 10.2165/00003088-197601020-00003. [DOI] [PubMed] [Google Scholar]